miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease that is mostly diagnosed late in the course of the illness. Unlike other cancers in which measurable successes have been achieved with traditional chemotherapy, targeted therapy, and, recently, immunotherapy, PDAC has proved to be poorly responsive to these treatments, with only marginal to modest incremental benefits using conventional cytotoxic therapy. There is, therefore, a great unmet need to develop better therapies based on improved understanding of biology and identification of predictive and prognostic biomarkers that would guide therapy.
Source: American Journal of Pathology - Category: Pathology Authors: Anteneh A. Tesfaye, Asfar S. Azmi, Philip A. Philip Tags: Review Source Type: research
More News: Adenocarcinoma | Biology | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Immunotherapy | Pancreas | Pancreatic Cancer | Pathology